

# Personalized Stem Cells Announces Treatment Milestone for FDA Approved Stem Cell Clinical Trial for Knee Arthritis

*Personalized Stem Cells, Inc. announces all clinical trial participants have been treated in their FDA approved stem cell clinical trial for knee osteoarthritis*

POWAY, CALIFORNIA, US, October 6, 2020 /EINPresswire.com/ -- [Personalized Stem Cells, Inc](#)



We are optimistic that the data will demonstrate the relative safety of autologous adipose-derived stem cell therapy for knee osteoarthritis.”

*Michael Dale, PSC President,  
COO*

(PSC), a human adipose-derived stem cell company, announces that all clinical trial participants have received treatment in the [FDA approved stem cell clinical trial for treatment of knee osteoarthritis](#). This treatment milestone comes just two months after the company announced the trial was fully enrolled. Clinical trial participants received one injection of their own stem cells into the affected knee.

PSC investigators will continue to collect data until all patient's have completed their final evaluation 84 days

after their treatment. The data will then be compiled and analyzed prior to FDA submission. Stem cell therapies/products are regulated by the FDA and must undergo a thorough approval process to assess the potential benefits versus the potential risks for the intended population.


PSC President, Michael Dale, stated, “This treatment milestone comes just eleven months after the first clinical trial participant was treated. We are optimistic that the data will demonstrate the relative safety of autologous adipose-derived stem cell therapy for knee osteoarthritis.” PSC aims to compile and submit clinical study data to the FDA in the first quarter of 2021, after which a Phase 2 blinded, placebo-controlled study will be launched. While Phase 1 studies focus on safety, the emphasis of Phase 2 studies is on effectiveness.

In addition to the knee trial, PSC recently received FDA approval to launch a clinical trial for the [treatment of COVID-19 patients with stem cells](#). This Phase 1 study will include 20 hospitalized patients in California. The company also plans to pursue FDA approval of stem cells for the treatment of back pain and traumatic brain injury (concussion), as well as arthritis affecting other joints.

## About Personalized Stem Cells, Inc.

Personalized Stem Cells was formed in 2018 to advance human regenerative medicine by securing FDA approval for serious diseases with limited treatment options. This privately held biopharmaceutical enterprise, based near San Diego (California), offers qualified physicians a GMP compliant stem cell product for use in approved clinical trials. PSC has licensed a portfolio of patents and applications in the field of regenerative medicine which includes patents covering treatment of lung diseases including COVID-19.

Michael Dale, President/COO  
Personalized Stem Cells, Inc  
+1 833-772-3557  
[email us here](#)



---

This press release can be viewed online at: <https://www.einpresswire.com/article/527739383>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.